Reata Pharmaceuticals Inc... (RETA)
NASDAQ: RETA
· Real-Time Price · USD
172.36
0.04 (0.02%)
At close: Sep 25, 2023, 10:00 PM
Reata Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 24.39M | 2.41M | 3.13M | 3.15M | 10M | 11.46M | 11.49M | 13.75M | 7.76M | 8.61M |
Cost of Revenue | 846K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 23.55M | 2.41M | 3.13M | 3.15M | 10M | 11.46M | 11.49M | 13.75M | 7.76M | 8.61M |
Operating Income | -59.48M | -316.46M | -270.07M | -270.18M | -257.72M | -253.9M | -244.73M | -227.15M | -223.44M | -213.87M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 104K | 104K |
Pretax Income | -87.68M | -354.23M | -311.93M | -311.54M | -304.38M | -304.18M | -297.84M | -278.6M | -272.3M | -266.53M |
Net Income | -80.06M | -346.61M | -309.69M | -309.57M | -304.63M | -303.77M | -297.39M | -277.78M | -271.39M | -266.27M |
Selling & General & Admin | 159.87M | 139.32M | 109.28M | 107.82M | 106.28M | 103.14M | 99M | 87.86M | 80.44M | 75.05M |
Research & Development | 203.31M | 185.52M | 169.84M | 164.24M | 160.18M | 160.92M | 155.99M | 151.84M | 149.59M | 146.31M |
Other Expenses | 733K | 1.11M | 789K | 512K | 244K | -63K | -27K | -27K | -31K | 3K |
Operating Expenses | 364.3M | 325.95M | 280.25M | 273.23M | 267.69M | 265.29M | 256.2M | 240.87M | 231.17M | 222.48M |
Interest Expense | 40.61M | 42.92M | 41.77M | 44.43M | 47.56M | 50.48M | 53.25M | 52.15M | 50.44M | 43.55M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 365.15M | 325.95M | 280.25M | 273.23M | 267.69M | 265.29M | 256.2M | 240.87M | 231.17M | 222.48M |
Income Tax Expense | 248K | -7.62M | -2.24M | -1.96M | 248K | -404K | -450K | -819K | -912K | -262K |
Shares Outstanding (Basic) | 41.51M | 36.95M | 36.32M | 36.54M | 36.47M | 36.41M | 36.39M | 36.39M | 36.3M | 36.2M |
Shares Outstanding (Diluted) | 41.51M | 36.95M | 36.32M | 36.54M | 36.47M | 36.41M | 36.39M | 36.39M | 36.3M | 36.2M |
EPS (Basic) | -2.33 | -9.47 | -8.5 | -8.5 | -8.37 | -8.35 | -8.18 | -7.73 | -7.7 | -7.73 |
EPS (Diluted) | -2.8 | -9.47 | -8.5 | -8.5 | -8.37 | -8.35 | -8.18 | -7.73 | -7.7 | -7.73 |
EBITDA | -102.46M | -358.46M | -311.93M | -265.95M | -255.62M | -238.99M | -229.91M | -204.73M | -200.17M | -208.48M |
EBIT | -67.84M | -324.12M | -277.3M | -267.11M | -256.82M | -240.21M | -231.1M | -212.95M | -208.37M | -216.67M |
Depreciation & Amortization | 1.13M | 1.11M | 1.13M | 1.18M | 1.23M | 1.24M | 1.21M | 1.17M | 1.14M | 1.13M |